← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

Traditional approvalTraditional conversionCervical cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Single-agent treatment of recurrent or metastatic cervical cancer with PD-L1 combined positive score of at least 1 by an FDA-approved test, after progression during or after chemotherapy.

LAMPGEN ANALYSIS

Why it matters

This converts the post-chemotherapy monotherapy indication and is distinct from the same-day combination approval.

What research teams should watch

Separate monotherapy from the first-line combination in abstraction and retain the prior chemotherapy date.

PRIMARY RECORDS

Sources